Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.51 |
| ▸ | HTT | P42858 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | GALR3 | O60755 | 2/20 | 0.45 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.45 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070088 | 0.76 | ALDH1A1 (0.45) | LMNASMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL14018738 | 0.74 | LMNA (0.59) | LMNASMN1; SMN2HTTALDH1A1NR2F2 | |
| SCHEMBL17372937 | 0.73 | NR2F2 (0.69) | LMNASMN1; SMN2HTTALDH1A1NR2F2 | |
| SCHEMBL15530474 | 0.73 | POLB (0.48) | LMNASMN1; SMN2HTTALDH1A1NR2F2 | |
| SCHEMBL17593233 | 0.72 | ALDH1A1 (0.50) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19197058 | 0.72 | SMN1; SMN2 (0.75) | LMNASMN1; SMN2HTTALDH1A1NR2F2 | |
| SCHEMBL5512562 | 0.71 | CA12 (0.41) | LMNASMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL4573318 | 0.70 | POLB (0.53) | LMNASMN1; SMN2HTTALDH1A1RAB9A | |
| SCHEMBL5293449 | 0.70 | ALDH1A1 (0.51) | LMNASMN1; SMN2HTTALDH1A1NR2F2 | |
| SCHEMBL27598153 | 0.69 | GLO1 (0.39) | LMNAHTTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122565-B2 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT LLC (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1326853-B1 | THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1326853-A1 | NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030045557-A1 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002028847-A1 | NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045557-A1 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | PDE3A, PDE3B, PDE7A | LMNA 3287/4885SMN1; SMN2 3049/4885HTT 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.